Japan’s Chugai today announced that it launched Elevidys intravenous infusion (delandistrogene moxeparvovec), which received ...

Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a U.S. appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular ...

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. | Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This ...

Regenxbio filed a lawsuit in 2020 alleging that Elevidys infringed a gene-therapy patent that the company licenses from ...

The global pharma giant cut more than 400 jobs in the state last year, after investing at least $360 million in its local manufacturing operations.

We expect investors to focus on pipeline updates when Keros Therapeutics KROS reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6.50 ...

This verdict could spell the end for Translarna’s decades-long and tumultuous US DMD development journey.

The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to-File letter in response to its application for mRNA-1010. Moderna will now ...

Lasting gains in swallowing ability have been reported for four people with oculopharyngeal muscular dystrophy given gene therapy in a trial.

Dosing has begun in a Phase 2 clinical trial testing the experimental oral therapy SAT-3247 in boys with Duchenne muscular ...